Hennion & Walsh Asset Management Inc. Raises Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Hennion & Walsh Asset Management Inc. grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 11.7% in the 4th quarter, HoldingsChannel reports. The firm owned 19,942 shares of the medical instruments supplier’s stock after purchasing an additional 2,094 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in LeMaitre Vascular were worth $1,837,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. boosted its position in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the period. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at $60,000. GAMMA Investing LLC boosted its holdings in LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 188 shares during the period. Canada Pension Plan Investment Board acquired a new position in LeMaitre Vascular during the 2nd quarter worth $82,000. Finally, Acadian Asset Management LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter worth about $104,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Activity

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

LMAT has been the subject of a number of analyst reports. Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $99.06 on Friday. LeMaitre Vascular, Inc. has a 1-year low of $56.04 and a 1-year high of $109.58. The stock has a market cap of $2.23 billion, a PE ratio of 54.13, a price-to-earnings-growth ratio of 2.07 and a beta of 0.96. The firm has a fifty day moving average price of $98.48 and a 200 day moving average price of $91.80.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.65%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.